Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1998-05-08
1999-06-22
Dees, Jose G.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
424 169, 424 111, 424 165, 530333, A61K 5100, A61M 3614
Patent
active
059140968
ABSTRACT:
Radioactive arsenic (.sup.72 As) labelled tissue specific ligands are prepared and used in the medical imaging of malignant breast or prostate tumors.
REFERENCES:
patent: 5169933 (1992-12-01), Anderson
patent: 5443816 (1995-08-01), Zamora et al.
patent: 5460785 (1995-10-01), Rhodes et al.
Hembrough et al, J. Biol. Chem (1996); vol. 271, No. 41, pp. 25684-25691 Cell Surface Cytokevatin-8 is the Major Plasminogen Receptor on Breast Cells.
Palmer et al (1997), J. Med. Chem; vol. 40, No. 5, pp. 749-753, (E) and (Z)-7-Aryldenenaltrexones: Synthesis and Radioligand Displacement Assays.
Fortunati et al (1996) Endocrinology vol. 137, No. 2, pp. 686-692, Sex-Steroid Binding Protein Exerts Negative Control on Estradiol Action in MCF-7 Cells(Human Breast Cancer) Through Cyclic Adenosin 3',5'-Monophosphate and Protein Kinase A..
Reubi (1995) J. Nuc. Med, vol. 36, No. 10, pp. 1846-1853, "In vitro Identification of Vasoactive Intestinal Receptors in Human Tumors: Implications for Tumor imaging".
Born Jerry L.
Palmer Robert B.
Dees Jos,e G.
Jones Dameron
University of New Mexico
LandOfFree
Arsenic-72 labeled compounds for tissue specific medical imaging does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arsenic-72 labeled compounds for tissue specific medical imaging, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arsenic-72 labeled compounds for tissue specific medical imaging will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1706732